Gammaglobulin - GigaGen
Alternative Names: High titer IVIG; IVIG - GigaGen; recombinant intravenous immunoglobulin - GigaGen; Recombinant IVIg - GigaGen; rIVIG - GigaGen; SCIG - GigaGenLatest Information Update: 28 Nov 2024
At a glance
- Originator GigaGen
- Class Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Immunodeficiency disorders
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Immunodeficiency-disorders in USA (IV)
- 24 Nov 2022 Preclinical development is still ongoing for Immunodeficiency disorders in USA (IV) (GigaGen pipeline, November 2022)
- 24 Nov 2022 Discontinued - Preclinical for Immunodeficiency disorders in USA (SC) before November 2022 (GigaGen pipeline, November 2022)